Literature DB >> 720380

Transplacental passage of atenolol in man.

A Melander, B Niklasson, I Ingemarsson, H Liedholm, B Scherstén, N O Sjöberg.   

Abstract

Maternal and umbilical serum concentrations of atenolol, a hydrophilic, cardioselective beta-adrenoceptor antagonist, were studied at delivery in seven cases of pregnancy hypertension. The drug had been administered to each patient for at least one week. Atenolol was detected in both maternal and umbilical serum in six cases, showing that there is transplacental passage of the drug. In the seventh case, who had stopped taking atenolol more than one day before delivery, neither maternal nor umbilical serum contained a measurable quantity of the drug. Atenolol concentration varied 3- to 6-fold between individuals, but there was no systematic difference between maternal and umbilical levels. It seems reasonable to assume that during steady state conditions the blood level of atenolol in mother and fetus is approximately equal, and that fetal accumulation of the drug does not occur.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 720380     DOI: 10.1007/bf00607437

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Atenolol in hypertension a study of long-term therapy.

Authors:  F J Zacharias; K J Cowen; P F Cuthbertson; T B Johnson; J Prestt; J Thompson; J Vickers; W T Simpson; R Tuson
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Comparison of propranolol and atenolol in hypertension.

Authors:  F J Zacharias; K J Cowen
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  The gas chromatographic determination of atenolol in biological samples.

Authors:  B Scales; P B Copsey
Journal:  J Pharm Pharmacol       Date:  1975-06       Impact factor: 3.765

Review 4.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

5.  A comparison of the antihypertensive effect of atenolol (ICI 66 082) and propranolol.

Authors:  L Hansson; A Westerlund; H Aberg; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

  5 in total
  16 in total

Review 1.  Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy.

Authors:  P M Kyle; C W Redman
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

Review 2.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Antihypertensive drugs in pregnancy.

Authors:  M deSwiet
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-10

4.  Toxicity of beta-blockers in a rat whole embryo culture: concentration-response relationships and tissue concentrations.

Authors:  S Klug; R Thiel; R Schwabe; H J Merker; D Neubert
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

5.  Atenolol: side effects in a newborn infant.

Authors:  D L Woods; D F Morrell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11

6.  Transfer of labetalol into amniotic fluid and breast milk in lactating women.

Authors:  N O Lunell; J Kulas; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 8.  Management of cardiac arrhythmias during pregnancy. Current concepts.

Authors:  H H Rotmensch; S Rotmensch; U Elkayam
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 9.  Hypertension in pregnancy. Pathophysiology and management.

Authors:  W F Lubbe
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

10.  Atenolol in the treatment of pregnancy-induced hypertension.

Authors:  K J Thorley; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.